Pharmaceutical. (1) The Supplier may in its absolute discretion determine from time to time a “Specified Order Quantity”, being the minimum order value or quantity for each order of Products to be supplied to Customer. Pharmaceutical orders with a value of less than A$500.00 will incur a service charge at Supplier’s discretion
(2) Two free into store/agreed deliver point(s) orders per month will be supplied providing each order has an invoice value of not less than A$500.00. Further orders may incur freight charges at Supplier’s discretion.
(3) Where Customer requires Supplier to freight the goods to Customer urgently, or in a manner which is not usually used by Supplier, Supplier reserves the right to charge Customer for any additional freight expenses incurred.
Pharmaceutical. (1) The Supplier will only supply restricted medicines where you hold the appropriate licence with the Medicines and Medical Devices Safety Authority to purchase such goods.
(2) The Supplier will only supply you with goods or services on credit when the Supplier has obtained a credit check satisfactory to the Supplier’s requirements
(3) The Supplier may in its absolute discretion determine from time to time a “Specified Order Quantity”, being the minimum order value or quantity for each order of products to be supplied to Customer. Pharmaceutical orders with a value of less than NZD$1,000.00 will incur a service charge at the Supplier’s discretion
(4) If an order has an invoice value of not less than NZD$1,000.00, Supplier will arrange for One Weekly Order to be supplied free to individually agreed delivery points (“Freight-Free Level”). Further orders may incur freight charges at Supplier’s discretion.
(5) Where Customer requires Supplier to freight the goods to Customer urgently, or in a manner which is not usually used by Supplier, Supplier reserves the right to charge Customer for any additional freight expenses incurred.
Pharmaceutical. (1) The Customer must notify the Supplier by telephone on +00 0 0000 0000 (immediately confirmed in writing) immediately after it becomes aware of any information (whether credible or otherwise) which may give rise to a recall of the goods.
(2) Without limiting clause (1) above, the Customer must notify the Supplier as soon as is practicable after it becomes aware of any adverse publicity or threatened or pending legal proceedings with respect to the goods or of any other information that might adversely impact upon the goodwill associated with the Supplier or the goods.
(3) The Customer will communicate any reports of Human Safety Information, quality complaints, or suspected counterfeits relating to the Supplier’s pharmaceutical products to GSK Australia Medical Information on 1800 033 109 or +00 0 0000 0000 within 24 hours of initial awareness.
Pharmaceutical. (1) The Customer must notify the Supplier by telephone on 0000 000 000 (immediately confirmed in writing) immediately after it becomes aware of any information (whether credible or otherwise) which may give rise to a recall of the goods.
(2) Without limiting clause (1) above, the Customer must notify the Supplier as soon as is practicable after it becomes aware of any adverse publicity or threatened or pending legal proceedings with respect to the goods or of any other information that might adversely impact upon the goodwill associated with the Supplier or the goods.
(3) The Customer will report technical or quality complaints or suspected counterfeits relating to pharmaceutical products to GSK New Zealand on 0800 808 500 or +00 00 000 0000 within 24 hours of initial awareness. Complaints samples if available must be securely retained and provided to the Supplier upon request.
Pharmaceutical. (1) The Customer must notify the Supplier by telephone on 0000 000 000(immediately confirmed in writing) immediately after it becomes aware of any information (whether credible or otherwise) which may give rise to a recall of the goods.
(2) Without limiting clause (1) above, the Customer must notify the Supplier as soon as is practicable after it becomes aware of any adverse publicity or threatened or pending legal proceedings with respect to the goods or of any other information that might adversely impact upon the goodwill associated with the Supplier or the goods.
(3) The Customer will communicate any reports of Human Safety Information, or suspected counterfeits relating to the Supplier’s pharmaceutical products to GSK Australia/NZ Medical Information on 0800 877 789 within 24 hours of initial awareness.
(4) The Customer will report technical or quality complaints relating to pharmaceutical products to GSK New Zealand on +00 00 000 0000 within 24 hours of initial awareness. Complaints samples if available must be securely retained and provided to the Supplier upon request.
Pharmaceutical. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all Applicable Laws, rules and...
Pharmaceutical particulars The capsules are not intended to be opened. Atomoxetine is an ocular irritant. In the unlikely event that the capsule contents come into contact with the eyes then the eyes should be flushed immediately with water.
Pharmaceutical. The Contractor shall provide a complete pharmaceutical system for inmates housed at the Facility. The Contractor will be responsible to pay the costs ofpharmaceuticals and pharmaceutical supplies as required by current applicable law. The cost for pharmaceuticals, medications and associated supplies required to treat blood or organ disease (i.e., hemophilia, hepatitis) shall be limited to $25,000.00 per year and shall be applied to the Maximum Limit defined in Section 1.9. Costs exceeding the $25,000.00 limit shall be the responsibility of the Agency. Non-reimbursed pharmaceutical costs incurred by the Contractor for providing health services to Federal Inmates (ICE, USM, FBOP, BIA, etc.) shall also be applied to the maximum financial limit established in Section 1.9. The maximum financial limit shall be pro-rated for any partial year of services. The Contractor shall provide for pharmaceutical services to assure the availability of prescribed medications within a reasonable time period ofthe order ofissue being written except where such medications are not readily available in the local community. Pharmaceutical services shall be consistent with State and Federal regulations and must be monitored by a licensed qualified pharmacist. The Agency agrees to allow the use of an Inmate's home medication, as appropriate, upon the verification of the medication by Contractor personnel. The Contractor shall provide for the recording of the administration of medications in a manner that includes documentation of the fact that inmates are receiving and ingesting their prescribed medications. Documentation will also be required when an inmate's ordered medication was not administered, or the wrong medication administered, and the acts and circumstances regarding the administration.
Pharmaceutical. (1) Pharmaceutical orders with a value of less than A$500.00 will incur a service charge.
(2) Two free into store orders per month will be supplied providing each order has an invoice value of not less than A$500.00. Further orders may incur freight charges. Freight will be charged on any urgent deliveries. Export orders are supplied in accordance with FCA Incoterms.
Pharmaceutical. Capsules
